Arno Therapeutics to Collaborate With Clarient for Development of Diagnostic Test
May 10 2013 - 8:00AM
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage
biopharmaceutical company focused on the development of oncology
therapeutics, today announced that it has signed an agreement with
Clarient Diagnostic Services, Inc., a GE Healthcare company, and
leading provider of cancer diagnostic testing, to develop a
diagnostic test to identify activated progesterone receptors in
endometrial cancer. The diagnostic test is intended to be used in
the development of Arno's investigational progestin receptor
antagonist, onapristone. In pre-clinical studies, the presence of
activated progesterone receptors (APR) has shown to be predictive
of onapristone activity.
Glenn Mattes, Chief Executive Officer and President of Arno,
stated: "Our collaboration with Clarient marks a significant
milestone for Arno and the development of onapristone. Clarient's
expertise and strength in cancer diagnostics makes them an ideal
partner to help us continue our investigation of onapristone and
move toward initiating a Phase I clinical study."
Using a novel immunohistochemistry process and analysis
developed by Arno, the diagnostic test will identify if APR are
present in tumor tissue. The APR diagnostic test will be used
in Arno's Phase I clinical study of onapristone, which the company
intends to begin in the second half of 2013.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company
developing innovative products for the treatment of
cancer. Arno has exclusive worldwide rights to develop and
market three innovative anti-cancer product candidates. These
compounds are in clinical or preclinical development as product
candidates to treat hematologic malignancies and solid tumors. For
more information about the company, please
visit www.arnothera.com.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. These statements are
often, but not always, made through the use of words or phrases
such as "anticipates," "expects," "plans," "believes," "intends,"
and similar words or phrases. These forward-looking statements
include, without limitation, statements regarding the timing,
progress and anticipated results of the clinical development of
onapristone, Arno's use of the diagnostic test being developed with
Clarient in its planned Phase I trial of onapristone, as well as
Arno's strategy, future operations, outlook, milestones, future
financial position, future financial results, plans and objectives.
We may not actually achieve these plans, intentions or expectations
and Arno cautions investors not to place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that we make. Such factors include,
among others, risks that the results of clinical trials will not
support our claims or beliefs concerning the effectiveness of
onapristone or any of our other product candidates, our ability to
finance the development of our product candidates, regulatory
risks, and our reliance on third party researchers and other
collaborators. Additional risks are described in the company's
Annual Report on Form 10-K for the year ended December 31, 2012.
Arno is providing this information as of the date of this press
release and does not undertake any obligation to update any
forward-looking statements as a result of new information, future
events or otherwise.
CONTACT: The Ruth Group
Stephanie Carrington (investors)
scarrington@theruthgroup.com
(646) 536-7017
Caitlin Cox (media)
ccox@theruthgroup.com
(646) 536-7033
Arno Therapeutics
Glenn Mattes
gm@arnothera.com
862-703-7176
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024